利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.011 秒)

    METHOD FOR IMMUNOLOGICALLY MEASURING SOLUBLE LR11
    1.
    发明申请
    METHOD FOR IMMUNOLOGICALLY MEASURING SOLUBLE LR11 有权
    免疫测定方法LR11

    公开(公告)号：US20140080158A1

    公开(公告)日：2014-03-20

    申请号：US14116683

    申请日：2012-05-09

    申请人： Kohei Takubo ,  Hiroyuki Ebinuma ,  Isamu Fukamachi ,  Hideaki Bujo ,  Yasushi Saito

    发明人： Kohei Takubo ,  Hiroyuki Ebinuma ,  Isamu Fukamachi ,  Hideaki Bujo ,  Yasushi Saito

    IPC分类号： G01N33/543

    CPC分类号： G01N33/54393 ,  G01N33/92

    摘要： To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample).The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.

    摘要翻译： 为了提供用于测定生物样品中可溶性LR11的方法，该方法通过免疫学手段实现了样品中存在的可溶性LR11的简单且准确的测定，而不需要从生物样品（例如血清样品）分离可溶性LR11。 用于免疫测定存在于生物样品中的可溶性LR11的本发明的方法，其特征在于所述方法包括用选自一种或多种磺基甜菜碱两性表面活性剂和一种或多种氨基磺基甜菜碱两性表面活性剂中的至少一种表面活性剂处理样品。

    Method for diagnosing malignant tumor
    3.
    发明授权
    Method for diagnosing malignant tumor 有权
    诊断恶性肿瘤的方法

    公开(公告)号：US09097714B2

    公开(公告)日：2015-08-04

    申请号：US13512903

    申请日：2010-12-15

    申请人： Hiroyuki Ebinuma ,  Kohei Takubo ,  Masanao Matsuo ,  Isamu Fukamachi ,  Hideaki Bujo ,  Chiaki Nakaseko ,  Yasushi Saito

    发明人： Hiroyuki Ebinuma ,  Kohei Takubo ,  Masanao Matsuo ,  Isamu Fukamachi ,  Hideaki Bujo ,  Chiaki Nakaseko ,  Yasushi Saito

    IPC分类号： G01N33/574 ,  G01N21/64 ,  G01N21/47 ,  G01N21/76 ,  G01N33/92

    CPC分类号： G01N33/574 ,  G01N33/57426 ,  G01N33/92 ,  G01N2800/52 ,  G01N2800/54

    摘要： To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence.The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.

    摘要翻译： 为了提供用于确定恶性肿瘤的存在或其严重性的方法和诊断试剂盒，选择其治疗方法或评价治疗方法的效果的方法或估计恶性肿瘤复发风险的方法 确定复发的存在或不存在。 用于确定恶性肿瘤的存在或其严重性的方法，用于选择其治疗方法或评估治疗方法的效果的方法，或用于估计恶性肿瘤复发风险的方法或是否存在恶性肿瘤 复发的特征在于包括1）测量源自受试者的样品中可溶性LR11的浓度和/或量的步骤，以及2）将上述测定值与从健康受试者获得的可溶性LR11的测定值进行比较的步骤 组。

    METHOD FOR DIAGNOSING MALIGNANT TUMOR
    5.
    发明申请
    METHOD FOR DIAGNOSING MALIGNANT TUMOR 有权
    诊断恶性肿瘤的方法

    公开(公告)号：US20130029363A1

    公开(公告)日：2013-01-31

    申请号：US13512903

    申请日：2010-12-15

    申请人： Hiroyuki Ebinuma ,  Kohei Takubo ,  Masanao Matsuo ,  Isamu Fukamachi ,  Hideaki Bujo ,  Chiaki Nakaseko ,  Yasushi Saito

    发明人： Hiroyuki Ebinuma ,  Kohei Takubo ,  Masanao Matsuo ,  Isamu Fukamachi ,  Hideaki Bujo ,  Chiaki Nakaseko ,  Yasushi Saito

    IPC分类号： G01N33/574 ,  G01N21/64 ,  G01N21/47 ,  G01N21/76

    CPC分类号： G01N33/574 ,  G01N33/57426 ,  G01N33/92 ,  G01N2800/52 ,  G01N2800/54

    摘要： To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence.The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.

    摘要翻译： 为了提供用于确定恶性肿瘤的存在或其严重性的方法和诊断试剂盒，选择其治疗方法或评价治疗方法的效果的方法或估计恶性肿瘤复发风险的方法 确定复发的存在或不存在。 用于确定恶性肿瘤的存在或其严重性的方法，用于选择其治疗方法或评估治疗方法的效果的方法，或用于估计恶性肿瘤复发风险的方法或是否存在恶性肿瘤 复发的特征在于包括1）测量源自受试者的样品中可溶性LR11的浓度和/或量的步骤，以及2）将上述测定值与从健康受试者获得的可溶性LR11的测定值进行比较的步骤 组。

    Method for immunologically measuring soluble LR11
    7.
    发明授权
    Method for immunologically measuring soluble LR11 有权
    免疫测定可溶性LR11的方法

    公开(公告)号：US09541550B2

    公开(公告)日：2017-01-10

    申请号：US14116683

    申请日：2012-05-09

    申请人： Kohei Takubo ,  Hiroyuki Ebinuma ,  Isamu Fukamachi ,  Hideaki Bujo ,  Yasushi Saito

    发明人： Kohei Takubo ,  Hiroyuki Ebinuma ,  Isamu Fukamachi ,  Hideaki Bujo ,  Yasushi Saito

    IPC分类号： G01N33/543 ,  G01N33/92

    CPC分类号： G01N33/54393 ,  G01N33/92

    摘要： To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample).The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.

    摘要翻译： 用于免疫测定存在于生物样品中的可溶性LR11的本发明的方法，其特征在于所述方法包括用选自一种或多种磺基甜菜碱两性表面活性剂和一种或多种氨基磺基甜菜碱两性表面活性剂中的至少一种表面活性剂处理样品。

    METHOD FOR QUANTIFICATION OF SOLUBLE LR11
    8.
    发明申请
    METHOD FOR QUANTIFICATION OF SOLUBLE LR11 审中-公开
    可溶性LR11的定量方法

    公开(公告)号：US20110091993A1

    公开(公告)日：2011-04-21

    申请号：US12933818

    申请日：2009-03-17

    申请人： Masanao Matsuo ,  Hiroyuki Ebinuma ,  Isamu Fukamachi ,  Hideaki Bujo ,  Yasushi Saito

    发明人： Masanao Matsuo ,  Hiroyuki Ebinuma ,  Isamu Fukamachi ,  Hideaki Bujo ,  Yasushi Saito

    IPC分类号： G01N33/566 ,  G01N33/68

    CPC分类号： G01N1/34 ,  C07K16/28 ,  G01N33/92

    摘要： Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.

    摘要翻译： 本发明提供了通过免疫学手段方便，准确地定量生物样品如血清中的可溶性LR11的方法，而不需要进行任何复杂的分离操作。 来自哺乳动物的样品中的可溶性LR11的免疫定量方法，包括用至少一种选自聚氧化烯烷基醚，聚氧化烯烷基苯基醚，烷基糖苷，烷硫基的表面活性剂处理样品的步骤 糖苷，酰基-N-甲基葡糖酰胺和胆酸盐。

    Monoclonal antibody against apolipoprotein A-I
    9.
    发明授权
    Monoclonal antibody against apolipoprotein A-I 有权
    针对载脂蛋白A-I的单克隆抗体

    公开(公告)号：US06828114B1

    公开(公告)日：2004-12-07

    申请号：US09857213

    申请日：2001-06-22

    申请人： Osamu Miyazaki ,  Isamu Fukamachi

    发明人： Osamu Miyazaki ,  Isamu Fukamachi

    IPC分类号： G01N33543

    CPC分类号： C07K16/18

    摘要： The present invention is drawn to a monoclonal antibody reacting specfically with (1) apoA-I occurring in HDL containing no apoA-II and having a molecular weight of 150,000 or less; and (2) apoA-I not binding to a lipid; a hybridoma producing this antibody; a method of immunologically assaying apoA-I characterized by reacting the antibody with a specimen; and an assay reagent for apoA-I which contains the antibody. The invention realizes measurement of a specific apoA-I, which provides a novel index of lipid metabolism disorder, etc.

    摘要翻译： 本发明涉及与（1）不含apoA-II且分子量为15万以下的HDL中发生的（1）apoA-I特异性反应的单克隆抗体。 和（2）apoA-I不与脂质结合; 产生该抗体的杂交瘤; 一种免疫测定apoA-I的方法，其特征在于使抗体与样品反应; 和含有该抗体的载脂蛋白A-1的测定试剂。 本发明实现了特异性apoA-I的测定，其提供了脂质代谢紊乱的新指标等。